Larvol Delta - Study-of-AU007-A-Monoclonal-Antibody-That-Binds-to-IL2-and-Inhibits-IL2R-Binding-in-Patients-With-Unresectable-Locally-Advanced-or-Metastatic-Cancer

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

imneskibart (AU-007) - Aulos Biosci

Bavencio (avelumab) - EMD Serono

Proleukin (aldesleukin) - Iovance Biotherap

http://clinicaltrials.gov/ct2/show/NCT05267626

Jul 31, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next